

## August 11, 2023 | Issue 283

## Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



CMS <u>suspended</u> its surprise billing independent dispute resolution (IDR) process after <u>a federal district judge</u> vacated the Administration's <u>IDR fee</u> increase.

IRS will release <u>a proposed rule</u> on excise tax reporting/payment for drug manufacturers refusing to participate in the Medicare Drug Price Negotiation Program.

FDA approved the <u>first oral treatment for postpartum depression</u> and Merck's <u>pediatric Ebola vaccine</u>.

DEA <u>may relax requirements</u> to allow <u>prescribing of some controlled</u> <u>substances via telemedicine</u> without in-person evaluation.

HRSA <u>awarded \$100M</u> to grow the nursing workforce... BARDA <u>awarded</u> <u>Cue Health a contract</u> to develop a multiplex test for influenza, RSV, and COVID-19.

---



Healthcare law and policy news

Supreme Court <u>blocked</u> Purdue Pharma's opioid <u>bankruptcy settlement</u> protecting the Sackler family from liability.

Healthcare merger and acquisition <u>volume in Q2 2023 was down</u> 7% from Q2 2022 and 41% from Q2 2021... Novo Nordisk is <u>acquiring Inversago</u> <u>Pharma</u> (\$1.1B)... Regeneron is <u>acquiring Decibel Therapeutics</u> (\$109M)... AstraZeneca will <u>partner with CanSino Biologics on</u> <u>developing/manufacturing</u> potential mRNA vaccines.

Novo Nordisk <u>reported its obesity drug</u>, <u>Wegovy</u>, <u>lowered cardiovascular</u> <u>risk</u> 20% in a clinical trial; Novo Nordisk will seek approval for expanded indication... Alliance for Regenerative Medicine <u>reported there are 1,600+</u> <u>cell and gene therapy clinical trials</u> this year, up from 1,000 in 2018.

A <u>NIH-CDC study found</u> just 22.5% of Americans with opioid use disorder received medication to treat the condition in 2021... A <u>Health Affairs study</u> found 2022 median commercial health plan prices for 46 procedures/services were <u>1.8 to 2.7 times more expensive than Medicare</u> Advantage prices at the same hospital... A <u>JAMA study found</u> that while original patents for FDA approvals increased 15%, the ratio of continuation patents increased 200% between 2000-2015.

A <u>research paper found</u>, between 2010 and 2020, hospitals on either side of a merger were <u>twice as likely to report a data breach</u> the year before and after close... KFF reported ACA marketplace insurers are <u>seeking median</u> <u>premium increases of 6%</u> for 2024.... AARP <u>reported the top 25 Medicare</u> <u>Part D drug by spend</u> increase 226%, on average, in price since market entry.

A <u>Bain survey found</u> 75% of health system leaders believe generative AI has reached a turning point in, but only 6% have a generative AI strategy.

-

Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please <u>click here</u>. If you wish to unsubscribe from all KPMG communications, please <u>click here</u>.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.